[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351567-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351567-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-associated-arterial-thrombosis-mechanisms-and-risk-factors-review","Cancer-Associated Arterial Thrombosis - Mechanisms and Risk Factors - Review","","Cancer-associated thrombosis (CAT) is a major driver of morbidity and mortality in cancer patients. Although venous thromboembolism has been studied extensively, arterial thrombosis in cancer—cancer-associated arterial thromboembolism (CA-ATE)—remains less understood and may carry heightened danger. The review analyzes how tumor microenvironment, cancer-cell biology, patient characteristics, and cancer therapies interact to promote CA-ATE, including endothelial injury, hypercoagulability, and platelet activation, while also summarizing therapy and patient risk determinants.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-associated-arterial-thrombosis-mechanisms-and-risk-factors-review/351567/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-associated-arterial-thrombosis-mechanisms-and-risk-factors-review/351567.png","ImageObject",300,407,{"name":42,"@type":43},"Aditya","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is cancer-associated arterial thromboembolism (CA-ATE) and why is it important?","Question",{"text":63,"@type":64},"CA-ATE refers to arterial thrombosis occurring in cancer patients. It is less well understood than venous disease but may pose greater clinical danger.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mechanisms drive CA-ATE according to the review?",{"text":68,"@type":64},"Key mechanisms include endothelial injury, hypercoagulability, and platelet activation, reflecting complex interactions between tumor and host factors.",{"name":70,"@type":61,"acceptedAnswer":71},"How do anticancer therapies and patient factors influence arterial thrombosis risk?",{"text":72,"@type":64},"Certain chemotherapeutic agents and targeted therapies are linked to increased arterial thrombosis risk, and patient age, cancer type, and cancer stage also contribute to higher CA-ATE risk.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351567,1790211465,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Tech Science Press  \n[https://doi. org/10.32604/or.2026.074452](https://doi. org/10.32604/or.2026.074452)  \nREVIEW  \nCancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors  \nKassiani Lalechou and Despoina Pantazi*  \nLaboratory of Biochemistry, Faculty of Chemistry, School of Sciences, University Campus, University of Ioannina, Ioannina, Greece *[Corresponding Author: Despoina Pantazi. Email: dpantazi@uoi.gr](Corresponding Author: Despoina Pantazi. Email: dpantazi@uoi.gr)  \n[Received: 11 October 2025](Received: 11 October 2025); [Accepted: 02 February 2026](Accepted: 02 February 2026); [Published: 22 April 2026](Published: 22 April 2026)  \nABSTRACT: Cancer-associated thrombosis (CAT) is a leading cause of morbidity and mortality among cancer patients. While venous thromboembolic events have been extensively studied due to their higher incidence, arterial thrombosis in cancer patients—referred to as cancer-associated arterial thromboembolism (CA-ATE)—is less well understood but may pose a greater danger. The pathophysiology of CA-ATE involves complex interactions between the tumor microenvironment, cancer cells, patient-related factors, and cancer therapies. Some chemotherapeutic agents, particularly platinum-based compounds (cisplatin, oxaliplatin), gemcitabine, taxanes, and targeted therapies such as tyrosine kinase inhibitors (TKIs), have been associated with an increased risk of arterial thrombosis. In certain patient populations, hormonal therapy and selective estrogen receptor modulators may also contribute to this risk. Additionally, factors such as patient age, cancer type, and stage contribute to an increased risk of arterial thrombosis in this population. Key mechanisms driving CA-ATE include endothelial injury, hypercoagulability, and platelet activation. Certain malignancies, notably lung and pancreatic cancers, are associated with a higher incidence of arterial thrombotic events. The aim of this review is to enhance understanding of the underlying mechanisms of cancer-related arterial thromboembolism and to highlight the various therapeutic, cancer-related, and patient-related factors that contribute to the occurrence of cancer-associated arterial thrombotic events.  \nKEYWORDS: Anticancer drugs; cancer-associated arterial thromboembolism; pathophysiology; risk factors; thrombosis  \n1 Introduction  \nThrombosis is the second leading cause of death in cancer patients, after cancer itself [1,2] . Cancer patients are at high risk of developing either venous thromboembolism (VTE) or arterial thromboembolism (ATE) [1,2] . The first report linking cancer to thrombosis dates back to 1865, when Armand Trousseau described the association between thrombosis and undiagnosed malignancy [3] . Cancer-associated thrombosis (CAT) remains one of the leading causes of non-cancer-related morbidity and mortality among cancer patients [4] . Both tumor microenvironment and anticancer therapies influence hemostatic mechanisms, contributing to thrombotic risk [2,4] .  \nThe tumor microenvironment is an important contributor to thrombosis [5]. However, in many patients, thrombosis may be the first clinical manifestation of cancer, often diagnosed within six months of the thrombotic event [6] . Patients with cancer face the risk of both venous and arterial thrombosis, which is more commonly associated with solid tumors but can also include disseminated intravascular coagulation [6] . Venous thromboembolism has been extensively studied, as it is the most frequent thrombotic complication in cancer patients [7] . Recently, however, there has been a notable increase in ATEs, attributed in part to  \nCopyright © 2026 The Authors. Published by Tech Science Press. This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nnewer chemotherapeutic agents. This underlines the need for further i","cbCaie3aizXY4U4U","https://ap.wps.com/l/cbCaie3aizXY4U4U","pdf",2168092,23,"English","# Introduction\n## Cancer-associated thrombosis and arterial thromboembolism\n## Therapeutic and patient-related risk factors\n# Pathophysiological mechanisms of CA-ATE\n## Endothelial injury, hypercoagulability, and platelet activation\n# Risk stratification and prevention strategies\n## Clinical tools and guideline recommendations","[{\"question\":\"What is cancer-associated arterial thromboembolism (CA-ATE) and why is it important?\",\"answer\":\"CA-ATE refers to arterial thrombosis occurring in cancer patients. It is less well understood than venous disease but may pose greater clinical danger.\"},{\"question\":\"Which mechanisms drive CA-ATE according to the review?\",\"answer\":\"Key mechanisms include endothelial injury, hypercoagulability, and platelet activation, reflecting complex interactions between tumor and host factors.\"},{\"question\":\"How do anticancer therapies and patient factors influence arterial thrombosis risk?\",\"answer\":\"Certain chemotherapeutic agents and targeted therapies are linked to increased arterial thrombosis risk, and patient age, cancer type, and cancer stage also contribute to higher CA-ATE risk.\"}]","Cancer-Associated Arterial Thrombosis - Mechanisms and Risk Factors - Review | PDF",1790094736,58,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/814264b4d072b53cd91bafb06b8ed58e.webp",983,1271,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4064a8a94d18e05dfcb8e76fb6dc215.webp",982,1270,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3652a2101ec65c11a3b694f8ad81cc74.webp",981,1269,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a6d78e100de9dd5857cb642b286ea36.webp",980,1267]